Protocol Review and Monitoring System (PRMS) The Protocol Review and Monitoring System (PRMS), called Protocol Review Committee (PRC) at the University of Pittsburgh Cancer Institute (UPCI) has responsibilities before and after trial activation. In the narrative it will be referred to as PRC/PRMS.
The specific aims of PRMS are to: 1) Provide scientific review of clinical protocols before submission to the Institutional Review Board (IRB), 2) Monitor open clinical trials for ongoing scientific merit and scientific progress, and 3) Close trials that fail to meet benchmarks for continued scientific merit and timely accrual. Prior to trial activation, PRC/PRMS reviews each protocol for scientific quality and priority. Once open, PRC/PRMS monitors each trial for ongoing scientific merit and progress. The goal of Protocol Review and Monitoring System (PRMS) is to promote the highest scientific quality and ensure efficient conduct of cancer clinical trials at UPCI and UPMC CancerCenter (UPMC CC). Clinical research is a tightly coordinated activity at UPCI where Clinical Protocol and Data Management (CPDM), the Data and Safety Monitoring Committee (DSMC) and PRC/PRMS work in concert. Importantly, the PRC/PRMS role in clinical research, to provide review and monitoring for scientific merit and progress, is distinct from the DSMC responsibility to ensure protocol safety and data quality. The PRC/PRMS also works in conjunction with three other parts of the clinical trials enterprise, the University of Pittsburgh IRB, the UPCI Biostatistics Facility, and the UPCI Disease Center teams. PRC/PRMS includes four committees (Committees A, B, C, and E). Committees A and B each meet once a month (off cycle) to provide coverage every 2 weeks to facilitate prompt review of cancer treatment protocols. Committee reviews all biobehavioral, cancer epidemiology, cancer prevention and control, and complementary medicine protocols as the need arises. Committee E was established in April, 2014 to provide Electronic review of industry trials, selected by the UPCI Director and/or Associate Director of Clinical Investigation, for expedited activation, for example, review of a study that uses a novel agent that might benefit a patient at UPCI and is already open at other sites. Membership of the PRC/PRMS includes a diverse group of cancer experts including medical, radiation, and surgical oncology, pharmacology, biostatistics, nursing, regulatory affairs, and laboratory scientists. PRC/PRMS members are appointed by the UPCI Director in consultation with the Associate Director for Clinical Investigation. The PRC/PRMS evaluates each protocol for study design, scientific quality, and availability of patient and financial resources required to complete the proposed trial. PRC/PRMS approval of cancer clinical trials is required before the study can be submitted to the University of Pittsburgh IRB, NCI CIRB or other accredited IRB. Once a trial is opened, the PRC/PRMS reviews for ongoing scientific merit and progress every six months. The PRC/PRMS has the authority to suspend or close any study that fails to meet the scientific requirements. Oversight for PRC/PRMS activities is provided by the UPCI Clinical Research Oversight Committee (CROC).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-28
Application #
9114520
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
28
Fiscal Year
2016
Total Cost
$91,699
Indirect Cost
$32,154
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Wang, Yue; Wang, Zehua; Xu, Jieni et al. (2018) Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun 9:3192
Lee, Young-Sun; Lee, Dae-Hee; Choudry, Haroon A et al. (2018) Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis. Mol Cancer Res 16:1073-1076
Tong, Jingshan; Zheng, Xingnan; Tan, Xiao et al. (2018) Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. Cancer Res 78:4704-4715
Menk, Ashley V; Scharping, Nicole E; Rivadeneira, Dayana B et al. (2018) 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med 215:1091-1100
Caves, Elizabeth A; Cook, Sarah A; Lee, Nara et al. (2018) Air-Liquid Interface Method To Study Epstein-Barr Virus Pathogenesis in Nasopharyngeal Epithelial Cells. mSphere 3:
Saydmohammed, Manush; Vollmer, Laura L; Onuoha, Ezenwa O et al. (2018) A High-Content Screen Reveals New Small-Molecule Enhancers of Ras/Mapk Signaling as Probes for Zebrafish Heart Development. Molecules 23:
Gough, Albert; Shun, Tong Ying; Taylor, D Lansing et al. (2018) Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies. Methods Mol Biol 1745:25-46
Fletcher, Rochelle; Wang, Yi-Jun; Schoen, Robert E et al. (2018) Colorectal cancer prevention: Immune modulation taking the stage. Biochim Biophys Acta Rev Cancer 1869:138-148
Li, Xiang; George, Subin M; Vernetti, Lawrence et al. (2018) A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX. Lab Chip 18:2614-2631
Singh, Renu; Mehrotra, Shailly; Gopalakrishnan, Mathangi et al. (2018) Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemother Pharmacol :

Showing the most recent 10 out of 1187 publications